Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2–dominated inflammatory response
Mónica G. Chiaramonte, … , Allen W. Cheever, Thomas A. Wynn
Mónica G. Chiaramonte, … , Allen W. Cheever, Thomas A. Wynn
Published September 15, 1999
Citation Information: J Clin Invest. 1999;104(6):777-785. https://doi.org/10.1172/JCI7325.
View: Text | PDF
Article Article has an altmetric score of 3

An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2–dominated inflammatory response

  • Text
  • PDF
Abstract

In schistosomiasis, chronic parasite egg–induced granuloma formation can lead to tissue destruction and fibrosis, which causes much of the morbidity and mortality associated with this disease. Here we show the importance of IL-13 in the pathogenesis of schistosomiasis, and demonstrate, perhaps for the first time, the therapeutic efficacy of an IL-13 inhibitor, sIL-13Rα2-Fc, in the control of hepatic fibrosis. T-helper type 2 (Th2) cytokines dominate the immune response in mice infected with Schistosoma mansoni, yet the specific contributions of IL-13 and IL-4 to the development of fibrosis were not previously investigated. Our studies demonstrate that both cytokines play redundant roles in granuloma formation, which explains the ability of IL-4–deficient mice to form granulomas around eggs. More importantly, however, these studies demonstrate that IL-13 is the dominant Th2-type cytokine regulating fibrosis. IL-13 stimulated collagen production in fibroblasts, and procollagen I and procollagen III mRNA expression was decreased in sIL-13Rα2-Fc–treated mice. Moreover, the reduction in fibrosis observed in IL-4–deficient mice was much less pronounced than that in sIL-13Rα2-Fc–treated animals. Fibrosis is a major pathological manifestation of a number of allergic, autoimmune, and infectious diseases. Thus, our findings provide evidence that IL-13 inhibitors may be of general therapeutic benefit in preventing damaging tissue fibrosis resulting from Th2-dominated inflammatory responses.

Authors

Mónica G. Chiaramonte, Debra D. Donaldson, Allen W. Cheever, Thomas A. Wynn

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 Total
Citations: 2 2 5 11 14 21 8 30 16 30 23 26 23 27 28 19 22 20 14 18 14 38 27 21 27 8 494
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article in year 2017 (16)

Title and authors Publication Year
Type 2 Cysteinyl Leukotriene Receptors Drive IL-33–Dependent Type 2 Immunopathology and Aspirin Sensitivity
T Liu, NA Barrett, Y Kanaoka, E Yoshimoto, D Garofalo, H Cirka, C Feng, JA Boyce
Journal of immunology (Baltimore, Md. : 1950) 2017
The Immunology of Cardiovascular Homeostasis and Pathology
S Sattler, T Kennedy-Lydon
The Immunology of Cardiovascular Homeostasis and Pathology 2017
The Immunology of Cardiovascular Homeostasis and Pathology
S Sattler, T Kennedy-Lydon
The Immunology of Cardiovascular Homeostasis and Pathology 2017
Recruited Monocytes and Type 2 Immunity Promote Lung Regeneration following Pneumonectomy
AJ Lechner, IH Driver, J Lee, CM Conroy, A Nagle, RM Locksley, JR Rock
Cell Stem Cell 2017
Radiation-Induced Fibrosis: Mechanisms and Opportunities to Mitigate. Report of an NCI Workshop, September 19, 2016
DE Citrin, PG Prasanna, AJ Walker, ML Freeman, I Eke, MH Barcellos-Hoff, MJ Arankalayil, EP Cohen, RC Wilkins, MM Ahmed, MS Anscher, B Movsas, JC Buchsbaum, MS Mendonca, TA Wynn, CN Coleman
Radiation Research 2017
Dioscin Exerts Protective Effects Against Crystalline Silica-induced Pulmonary Fibrosis in Mice
C Li, Y Lu, S Du, S Li, Y Zhang, F Liu, Y Chen, D Weng, J Chen
Theranostics 2017
Review: Frontiers of Antifibrotic Therapy in Systemic Sclerosis: ANTIFIBROTIC THERAPY IN SSc
JH Distler, C Feghali-Bostwick, A Soare, Y Asano, O Distler, DJ Abraham
Arthritis & Rheumatology 2017
Hydrolysis of Hyaluronic Acid in Lymphedematous Tissue Alleviates Fibrogenesis via TH1 Cell-Mediated Cytokine Expression
S Cho, K Roh, J Park, YS Park, M Lee, S Cho, EJ Kil, MJ Cho, JS Oh, HS Byun, SH Cho, K Park, H Kang, J Koo, CH Yeom, S Lee
Scientific Reports 2017
Clonorchis sinensis lysophospholipase A upregulates IL-25 expression in macrophages as a potential pathway to liver fibrosis
L Zhou, M Shi, L Zhao, Z Lin, Z Tang, H Sun, T Chen, Z Lv, J Xu, Y Huang, X Yu
Parasites & vectors 2017
Type 2 immunity in tissue repair and fibrosis
RL Gieseck, MS Wilson, TA Wynn
Nature Reviews Immunology 2017
Stromal and immune cells in gut fibrosis: the myofibroblast and the scarface
V Valatas
Annals of Gastroenterology 2017
Host regulation of liver fibroproliferative pathology during experimental schistosomiasis via interleukin-4 receptor alpha
JK Nono, H Ndlovu, NA Aziz, T Mpotje, L Hlaka, F Brombacher, SJ Davies
PLoS neglected tropical diseases 2017
A comparative analysis of the molecular basis of fibrosis between tissues
R Miller, M Fell, J Pleat
Comparative Clinical Pathology 2017
Therapeutic pro-fibrogenic signaling pathways in fibroblasts
S Cannito, E Novo, M Parola
Advanced Drug Delivery Reviews 2017
Radiation-Induced Fibrosis: Mechanisms and Opportunities to Mitigate. Report of an NCI Workshop, September 19, 2016
DE Citrin, PG Prasanna, AJ Walker, ML Freeman, I Eke, MH Barcellos-Hoff, MJ Arankalayil, EP Cohen, RC Wilkins, MM Ahmed, MS Anscher, B Movsas, JC Buchsbaum, MS Mendonca, TA Wynn, CN Coleman
Radiation Research 2017
Thoracic Irradiation Recruit M2 Macrophage into the Lung, Leading to Pneumonitis and Pulmonary Fibrosis
HR Park, SK Jo, U Jung
2017

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 29 patents
183 readers on Mendeley
See more details